source
- Amgen's Repatha shows reduced heart attack risk while Satellos alters Duchenne trial endpointSatellos Bioscience announced a change to the primary endpoint of its ongoing Duchenne muscular dystrophy trial of the investigational small‑molecule forazapadin, shifting focus to a measure of mus…
- Eli Lilly partners with Hims & Hers to sell Zepbound and Foundayo via telehealth platformEli Lilly announced a partnership with Hims & Hers to make its obesity treatments Zepbound and Foundayo available through the telehealth service. The arrangement lets patients with a prescription…